Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Efficacy and Safety Study of Nalbuphine ER Tablets for the Treatment of Refractory Chronic Cough

NCT05962151 is registered in ClinicalTrials.gov with Trevi Therapeutics as lead sponsor.

NCT NCT05962151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05962151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Efficacy and Safety Study of Nalbuphine ER Tablets for the Treatment of Refractory Chronic Cough
Lead sponsor
Trevi Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2023
Completion date
January 6, 2025
Enrollment
66 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

refractory chronic cough